<?xml version="1.0" encoding="UTF-8"?>
<notes>
 <p content-type="self-citation">
  <mixed-citation publication-type="journal" id="ajh25238-cit-9001">
   <string-name>
    <surname>Cortes</surname>
    <given-names>JE</given-names>
   </string-name>, 
   <string-name>
    <surname>Douglas Smith</surname>
    <given-names>B</given-names>
   </string-name>, 
   <string-name>
    <surname>Wang</surname>
    <given-names>ES</given-names>
   </string-name>, et al. 
   <article-title>Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results</article-title>. 
   <source xml:lang="en">Am J Hematol</source>. 
   <year>2018</year>;
   <volume>93</volume>
   <fpage>1301</fpage>–
   <lpage>1310</lpage>. 
   <pub-id pub-id-type="doi">10.1002/ajh.25238</pub-id>
   <pub-id pub-id-type="pmid">30074259</pub-id>
  </mixed-citation>
 </p>
 <fn-group id="ajh25238-ntgp-0001">
  <fn id="ajh25238-note-0001">
   <p>Presented in abstract and poster form at the 22nd annual meeting of the European Hematology Association, Madrid, Spain, June 22‐25, 2017.</p>
  </fn>
  <fn id="ajh25238-note-0501">
   <p>
    <bold>Funding information</bold> Pfizer Inc.
   </p>
  </fn>
 </fn-group>
</notes>
